This retrospective real-world study aims to answer the need to understand the outcomes and healthcare resource utilization (HCRU) of patients with locally advanced and unresectable or metastatic NSCLC stratified by the KRAS status. This evidence concerns the gene KRAS and non-small cell lung carcinoma.